Zoledronic acid in patients with stage IIIA/B NSCLC: Results of a randomized, phase III study

Annals of Oncology

Volumn 23, Issue 8, 2012, Pages 2082-2087

  Scagliotti, G V ^a   Kosmidis, P ^b   De Marinis, F ^c   Schreurs, A J M ^d   Albert, I ^e   Engel Riedel, W ^f   Schallier, D ^g   Barbera, S ^h   Kuo, H P ⁱ   Sallo, V ^j   Perez, J R ^j   Manegold, C ^k  

^a UNIVERSITY OF TURIN   (Italy)

^b HYGEIA HOSPITAL   (Greece)

^c SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^d JEROEN BOSCH HOSPITAL   (Netherlands)

^e Mátrai Gyógyintézet ^*  (Hungary)

^f Department of Medical Oncology   (Germany)

^g UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^h Mariano Santo Hospital   (Italy)

ⁱ CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^j NOVARTIS PHARMA AG   (Switzerland)

^k UNIVERSITY OF HEIDELBERG   (Germany)

more..

Author keywords

Adjuvant treatment; Non small cell lung cancer; Survival; Zoledronic acid

Indexed keywords

CALCIUM; VITAMIN D; ZOLEDRONIC ACID;

ADULT; AGED; ARTICLE; BONE METASTASIS; CANCER STAGING; CONSTIPATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FOLLOW UP; HUMAN; JAW OSTEONECROSIS; KIDNEY DYSFUNCTION; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; ORTHOPEDIC SURGERY; OVERALL SURVIVAL; PATHOLOGIC FRACTURE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIOTHERAPY; RANDOMIZED CONTROLLED TRIAL; SPINAL CORD COMPRESSION;

EID: 84864955288     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds128     Document Type: Article

References (24)

1. Ferlay J, Shin HR, Bray F et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-2917.
2. Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001; 27: 165-176.
3. Ettinger DS, Akerley W, Bepler G et al. Non-small cell lung cancer. J Natl Compr Canc Netw 2008; 6: 228-269.
4. De Marinis F, Eberhardt W, Harper PG et al. Bisphosphonate use in patients with lung cancer and bone metastases: recommendations of a European expert panel. J Thorac Oncol 2009; 4: 1280-1288.
5. Neville-Webbe HL, Gnant M, Coleman RE. Potential anticancer properties of bisphosphonates. Semin Oncol 2010; 37(Suppl. 1): S53-S65.
6. Lipton A, Cook R, Saad F et al. Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid. Cancer 2008; 113: 193-201.
7. Zarogoulidis K, Boutsikou E, Zarogoulidis P et al. The impact of zoledronic acid therapy in survival of lung cancer patients with bone metastasis. Int J Cancer 2009; 125: 1705-1709.
8. Costa L, Cook R, Body J-J et al. Zoledronic acid delays disease progression and improves survival in patients with bone metastases from solid tumors and elevated levels of bone resorption. In The IX International Meeting on Cancer Induced Bone Disease (Poster 50), Arlington, VA, 2009.
9. Mystakidou K, Katsouda E, Parpa E et al. Randomized, open label, prospective study on the effect of zoledronic acid on the prevention of bone metastases in patients with recurrent solid tumors that did not present with bone metastases at baseline. Med Oncol 2005; 22: 195-201.
10. Zometa® (zoledronic acid) injection [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation 2011.
11. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
12. Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events v3.0 (CTCAE) 2006; http://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcaev3.pdf (29 August 2011, date last accessed).
13. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
14. Reboul FL. Radiotherapy and chemotherapy in locally advanced non-small cell lung cancer: preclinical and early clinical data. Hematol Oncol Clin North Am 2004; 18: 41-53.
15. Hirsh V, Major PP, Lipton A et al. Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity. J Thorac Oncol 2008; 3: 228-236.
16. Bidard FC, Vincent-Salomon A, Gomme S et al. Disseminated tumor cells of breast cancer patients: a strong prognostic factor for distant and local relapse. Clin Cancer Res 2008; 14: 3306-3311.
17. Braun S, Vogl FD, Naume B et al. A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 2005; 353: 793-802.
18. Aft R, Naughton M, Trinkaus K et al. Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. Lancet Oncol 2010; 11: 421-428.
19. Tsuya A, Kurata T, Tamura K, Fukuoka M. Skeletal metastases in non-small cell lung cancer: a retrospective study. Lung Cancer 2007; 57: 229-232.
20. Pandya KJ, Gajra A, Warsi GM et al. Multicenter, randomized, phase 2 study of zoledronic acid in combination with docetaxel and carboplatin in patients with unresectable stage IIIB or stage IV non-small cell lung cancer. Lung Cancer 2010; 67: 330-338.
21. Santini D, Vincenzi B, Dicuonzo G et al. Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. Clin Cancer Res 2003; 9: 2893-2897.
22. Kondo M, Sakuta K, Noguchi A et al. Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy. Cytotherapy 2008; 10: 842-856.
23. Sato K, Kimura S, Segawa H et al. Cytotoxic effects of gammadelta T cells expanded ex vivo by a third generation bisphosphonate for cancer immunotherapy. Int J Cancer 2005; 116: 94-99.
24. Schirrmeister H, Arslandemir C, Glatting G et al. Omission of bone scanning according to staging guidelines leads to futile therapy in non-small cell lung cancer. Eur J Nucl Med Mol Imaging 2004; 31: 964-968.